AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation

Lyons, John F; Grimshaw, Kyla M; Woodhead, Steven J; Feltell, Ruth E; Reule, Matthias; Smyth, Tomko; Seavers, Lisa C; Harada, Isobelle; Higgins, Jacqueline; Smith, Donna M; Fazal, Lynsey; Workman, Paul; Collins, Ian; Garrett, Michelle D; Thompson, Neil T

AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation

journal contribution

posted on 2024-07-31, 01:50 authored by John F Lyons, Kyla M Grimshaw, Steven J Woodhead, Ruth E Feltell, Matthias Reule, Tomko Smyth, Lisa C Seavers, Isobelle Harada, Jacqueline Higgins, Donna M Smith, Lynsey Fazal, Paul Workman, Ian CollinsIan Collins, Michelle D Garrett, Neil T Thompson

AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation

History

Journal

MOLECULAR CANCER THERAPEUTICS

Volume

6

Pagination

3512S-3512S

ISSN

1535-7163

Language

English

Publication classification

E3.1 Extract of paper

Issue

12

Publisher

AMER ASSOC CANCER RESEARCH

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology

AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation

History

Journal

Volume

Pagination

ISSN

Language

Publication classification

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports